INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us

Late Phase Studies

Indero supports late stage clinical development, empowering dermatology and rheumatology researchers to demonstrate efficacy and safety through phase 2b-3 studies.

Manage Costs & Mitigate Risks With Late Phase Clinical Research

Indero’s dermatology and rheumatology experts evaluate protocol and recruitment objectives to ensure the successful execution of late phase trials. With extensive site connections across the globe and the ability to handle large, multicenter studies, Indero can get your study where it needs to go—meeting your timelines and quality requirements.

Late Phase Studies
225 +
Clinical Trials
475 +
Investigators
2975 +
Indications
25 +

Late Phase Study Capabilities

Late phase studies provide critical insights into long-term safety, efficacy, and real-world applications, ensuring treatments meet regulatory and patient needs. Indero’s extensive experience in dermatology and rheumatology trials and deep understanding of immune-mediated conditions positions us as a trusted partner for late phase studies at scale.

Project Management

Our project managers have extensive dermatology and rheumatology experience in all phases of clinical trials, offering leadership and support to sponsors at every stage.

Site Network

We have strong relationships with sites across the world that can meet your requirements for everything from recruitment and retention to timelines and quality.

Innovative Patient Recruitment

We have a dedicated patient recruitment and advertising team working alongside our project management team to build innovative strategies specifically customized for your late phase clinical trials.

Clinical Monitoring

Indero has a team of Clinical Research Associates (CRAs) with capabilities to support all sites in North America, Europe, Latin America, and Asia Pacific. This allows us to rapidly assemble a flexible monitoring team depending on site location, project needs, and monitoring plan requirements.

Geographical Footprint

Indero’s integrated services span the entire world, with capabilities in North America, Europe, Latin America, and Asia Pacific. Wherever you need to take your trial to ensure genetic diversity among subjects, we can support you.

Biometrics

Indero uses validated and robust in-house data management systems to deliver customized biometrics services. We focus on understanding the sponsor’s goals and study objectives, which ensures the ideal methods for data collection and analysis.

Late Phase Study Services

Late phase clinical trials help dermatology and rheumatology researchers assess the market readiness of new treatments and monitor for potential long-term side effects at scale. Indero specializes in delivering comprehensive solutions for late phase trials, providing robust evidence of a drug’s efficacy and safety in a diverse patient population. Our services include:

  • Late phase study design
  • Site selection and management
  • Patient recruitment
  • Project management 
  • Regulatory and clinical development consulting
  • Clinical monitoring
  • Biostatistics and data management
  • Medical writing
  • Medical monitoring
  • Pharmacovigilance
  • Quality assurance

Dermatology Studies

Rheumatology Studies

Snehal Naik, PhD

Senior Vice President,
Clinical Development

“The expertise and motivation Indero brought to the table were pivotal to our success. From the initial synopsis development to the final stages of study conduct, the synergy between our teams was palpable and was underpinned by Innovaderm’s strong relationships with sites, investigators, and KOLs.”

 Dermatology & Rheumatology Indications for Late Phase Studies

Indero can support late phase studies across a wide range of dermatology and rheumatology indications, including:

  • Atopic dermatitis
  • Psoriasis
  • Alopecia areata
  • Hidradenitis suppurativa
  • Chronic inducible urticaria
  • Chronic spontaneous urticaria
  • Vitiligo
  • Acne
  • Rosacea
  • Chronic hand eczema
  • Notalgia paresthetica
  • Actinic keratosis
  • GPP, PPP, and PPPP
  • Hyperhidrosis
  • Prurigo nodularis
  • Onychomycosis
  • Cosmetics and aesthetics
  • Rheumatoid arthritis
  • Osteoarthritis
  • Radiographic (ankylosing spondylitis) and non-radiographic axial spondyloarthritis
  • Psoriatic arthritis
  • Systemic lupus erythematosus (SLE) and juvenile SLE
  • Lupus nephritis
  • Idiopathic inflammatory myopathies, including polymyositis and dermatomyositis
  • Sjögren’s disease
  • Systemic sclerosis (scleroderma)
  • Osteoporosis

Atopic Dermatitis Phase 3 Study Reaches 200% Enrollment within First 5 Months

Indero successfully managed a Phase 3 atopic dermatitis program testing a topical treatment, which included four studies across the USA, Canada, and Europe.

Challenges

  • Site selection: 
    • Very competitive and saturated indication in North America
  • Recruitment: 
    • Recruitment slowed down after open-label extension (OLE) enrollment was completed
  • Photography:
    • Material shipment and site training impacted site’s activation timelines

Strategy

  • Evaluated expansion in other regions than North America
  • Supplement site recruitment activities with substantial digital central advertisement programs
  • Conducted follow-up with sites to ensure photograph training was completed on schedule
  • Shipped photography material in conjunction with site contract signature for a streamlined activation timeline

Wherever You’re Going, We’re all in.

Need help with your next study? We want to learn more. Fill out the form on the right and one of our experts will be in touch.

Talk to us

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte prĂšs de 30 ans d’expĂ©rience dans l’industrie pharmaceutique et CRO, s’Ă©tant distinguĂ© par son leadership exceptionnel, sa vision stratĂ©gique et son innovation. L’expertise de Jeff couvre des opĂ©rations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matiĂšre de crĂ©ation de valeur, de gestion des partenaires et d’opĂ©rations CRO ont toujours contribuĂ© au succĂšs dans ses fonctions prĂ©cĂ©dentes. Sous la direction de Jeff, Indero continue d’étendre ses capacitĂ©s, faisant progresser les connaissances mĂ©dicales et les nouvelles thĂ©rapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≀3 days, and lowers costs, helping teams make informed go/no-go decisions faster.
LEARN MORE >